Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 188

1.

Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer.

Nakanishi R, Harada J, Tuul M, Zhao Y, Ando K, Saeki H, Oki E, Ohga T, Kitao H, Kakeji Y, Maehara Y.

Int J Clin Oncol. 2013 Dec;18(6):1042-8. doi: 10.1007/s10147-012-0501-x. Epub 2012 Nov 29.

PMID:
23188063
2.

Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer.

Kadowaki S, Kakuta M, Takahashi S, Takahashi A, Arai Y, Nishimura Y, Yatsuoka T, Ooki A, Yamaguchi K, Matsuo K, Muro K, Akagi K.

World J Gastroenterol. 2015 Jan 28;21(4):1275-83. doi: 10.3748/wjg.v21.i4.1275.

3.

A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.

Kawazoe A, Shitara K, Fukuoka S, Kuboki Y, Bando H, Okamoto W, Kojima T, Fuse N, Yamanaka T, Doi T, Ohtsu A, Yoshino T.

BMC Cancer. 2015 Apr 11;15:258. doi: 10.1186/s12885-015-1276-z.

4.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A.

J Clin Oncol. 2008 Dec 10;26(35):5705-12. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10.

5.

Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.

Soeda H, Shimodaira H, Watanabe M, Suzuki T, Gamoh M, Mori T, Komine K, Iwama N, Kato S, Ishioka C.

Int J Clin Oncol. 2013 Aug;18(4):670-7. doi: 10.1007/s10147-012-0422-8. Epub 2012 May 26.

PMID:
22638623
6.

EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study.

Schweiger T, Hegedüs B, Nikolowsky C, Hegedüs Z, Szirtes I, Mair R, Birner P, Döme B, Lang G, Klepetko W, Ankersmit HJ, Hoetzenecker K.

Ann Surg Oncol. 2014 Mar;21(3):946-54. doi: 10.1245/s10434-013-3386-7. Epub 2013 Nov 27.

PMID:
24281417
7.

Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.

Cushman-Vokoun AM, Stover DG, Zhao Z, Koehler EA, Berlin JD, Vnencak-Jones CL.

Clin Colorectal Cancer. 2013 Sep;12(3):168-78. doi: 10.1016/j.clcc.2013.04.005. Epub 2013 Jun 14.

8.

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio N, Catalano V, Tonini G, Magnani M, Fontanini G, Basolo F, Falcone A, Graziano F.

Br J Cancer. 2009 Aug 18;101(4):715-21. doi: 10.1038/sj.bjc.6605177. Epub 2009 Jul 14.

9.

Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer.

Popovici V, Budinska E, Bosman FT, Tejpar S, Roth AD, Delorenzi M.

BMC Cancer. 2013 Sep 27;13:439. doi: 10.1186/1471-2407-13-439.

10.
11.

Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.

Umeda Y, Nagasaka T, Mori Y, Sadamori H, Sun DS, Shinoura S, Yoshida R, Satoh D, Nobuoka D, Utsumi M, Yoshida K, Yagi T, Fujiwara T.

J Hepatobiliary Pancreat Sci. 2013 Feb;20(2):223-33. doi: 10.1007/s00534-012-0531-9.

PMID:
23010994
12.

Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review.

Imamura Y, Lochhead P, Yamauchi M, Kuchiba A, Qian ZR, Liao X, Nishihara R, Jung S, Wu K, Nosho K, Wang YE, Peng S, Bass AJ, Haigis KM, Meyerhardt JA, Chan AT, Fuchs CS, Ogino S.

Mol Cancer. 2014 May 31;13:135. doi: 10.1186/1476-4598-13-135.

13.

Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.

Sinicrope FA, Shi Q, Smyrk TC, Thibodeau SN, Dienstmann R, Guinney J, Bot BM, Tejpar S, Delorenzi M, Goldberg RM, Mahoney M, Sargent DJ, Alberts SR.

Gastroenterology. 2015 Jan;148(1):88-99. doi: 10.1053/j.gastro.2014.09.041. Epub 2014 Oct 8.

14.

Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?

Rizzo S, Bronte G, Fanale D, Corsini L, Silvestris N, Santini D, Gulotta G, Bazan V, Gebbia N, Fulfaro F, Russo A.

Cancer Treat Rev. 2010 Nov;36 Suppl 3:S56-61. doi: 10.1016/S0305-7372(10)70021-9. Review.

PMID:
21129611
15.

Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.

Schirripa M, Cremolini C, Loupakis F, Morvillo M, Bergamo F, Zoratto F, Salvatore L, Antoniotti C, Marmorino F, Sensi E, Lupi C, Fontanini G, De Gregorio V, Giannini R, Basolo F, Masi G, Falcone A.

Int J Cancer. 2015 Jan 1;136(1):83-90. doi: 10.1002/ijc.28955. Epub 2014 May 28.

16.

BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy.

Teng HW, Huang YC, Lin JK, Chen WS, Lin TC, Jiang JK, Yen CC, Li AF, Wang HW, Chang SC, Lan YT, Lin CC, Wang HS, Yang SH.

J Surg Oncol. 2012 Aug 1;106(2):123-9. doi: 10.1002/jso.23063. Epub 2012 Feb 13.

PMID:
22331825
17.

Association between molecular subtypes of colorectal cancer and patient survival.

Phipps AI, Limburg PJ, Baron JA, Burnett-Hartman AN, Weisenberger DJ, Laird PW, Sinicrope FA, Rosty C, Buchanan DD, Potter JD, Newcomb PA.

Gastroenterology. 2015 Jan;148(1):77-87.e2. doi: 10.1053/j.gastro.2014.09.038. Epub 2014 Sep 30.

18.

The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.

Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M.

Acta Oncol. 2014 Jul;53(7):852-64. doi: 10.3109/0284186X.2014.895036. Epub 2014 Mar 25. Review.

PMID:
24666267
19.

Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.

Shen Y, Wang J, Han X, Yang H, Wang S, Lin D, Shi Y.

PLoS One. 2013 Dec 10;8(12):e81628. doi: 10.1371/journal.pone.0081628. eCollection 2013.

20.

Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.

Lee S, Cho NY, Choi M, Yoo EJ, Kim JH, Kang GH.

Pathol Int. 2008 Feb;58(2):104-13. doi: 10.1111/j.1440-1827.2007.02197.x.

PMID:
18199160

Supplemental Content

Support Center